Post-Interleukin 6

Aus coViki
Wechseln zu: Navigation, Suche

siltuximab, tocilizumab, SGP130Fc, sarilumab, clazakizumab

  • GET 2020. COVID-19 pneumonia treated with Sarilumab: A clinical series of eight patients. Extract
  • GET 2020. Supportive Treatment with Tocilizumab for COVID-19: A Systematic Review Extract
  • GET ä. Tocilizumab, an anti-IL6 receptor antibody, to treat Covid-19-related respiratory failure: a case report Extract
  • GET 2020. First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab Extract
  • GET ä. Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report Extract
  • GET ä. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia Extract
  • GET 2020. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19 Extract
  • GET 2020. Treat 2019 novel coronavirus (COVID-19) with IL-6 inhibitor: Are we already that far? Extract
  • GET ä. The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality Extract
  • GET ä. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies Extract
  • GET ä. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)? Extract
  • GET 2020. Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19 Extract
  • GET 2020. Anti-IL6R role in treatment of COVID-19-related ARDS Extract
  • GET 2020. Why tocilizumab could be an effective treatment for severe COVID-19? Extract
  • GET ä. SARS-CoV-2-mediated inflammatory response in lungs: should we look at RAGE? Extract
  • GET 2020. Fyrsta meethfereth meeth tocilizumab vieth COVID-19 herlendis - sjukratilfelli Extract
  • GET ä. Translating IL-6 biology into effective treatments Extract
  • GET ä. Tocilizumab: A new opportunity in the possible therapeutic arsenal against COVID-19 Extract
  • GET ä. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection Extract
  • GET 2020. Clinical Course of COVID-19 in a Liver Transplant Recipient on Hemodialysis and Response to Tocilizumab Therapy: A Case Report Extract
  • GET 2020. COVID-19 pneumonia in a kidney transplant recipient successfully treated with tocilizumab and hydroxychloroquine Extract
  • GET ä. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Extract
  • GET ä. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy Extract
  • GET 2020. Antirheumatic agents in covid-19: is IL-6 the right target? Extract
  • GET 2020. Interleukin 6-blockade treatment for severe COVID-19 in two patients with multiple myeloma Extract
  • GET 2020. Favorable changes of CT findings in a patient with COVID-19 pneumonia after treatment with tocilizumab Extract
  • GET 2020. Facing the SARS-CoV-2 (COVID-19) outbreak with IL-6R antagonists Extract
  • GET 2020. Tocilizumab treatment in COVID-19: A single center experience Extract
  • GET 2020. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies Extract
  • GET 2020. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws Extract
  • GET 2020. Tocilizumab for the treatment of severe coronavirus disease 2019 Extract
  • GET 2020. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection Extract
  • GET 2020. Dramatic improvement after tocilizumab of severe COVID-19 in a child with sickle cell disease and acute chest syndrome Extract
  • GET 2020. Rapid and severe Covid-19 pneumonia with severe acute chest syndrome in a sickle cell patient successfully treated with tocilizumab Extract
  • GET ä. Case Study: A Patient with Asthma, Covid-19 Pneumonia and Cytokine Release Syndrome Treated with Corticosteroids and Tocilizumab Extract
  • GET 2020. Effective treatment of severe COVID-19 patients with tocilizumab Extract
  • GET ä. Combined treatment of tocilizumab and chloroquine on severe COVID-19: a case report Extract
  • GET 2020. Tocilizumab for cytokine storm syndrome in COVID-19 pneumonia: an increased risk for candidemia? Extract
  • GET 2020. Why judiciously timed anti-IL 6 therapy may be of benefit in severe COVID-19 infection Extract
  • GET ä. Perforacion intestinal en paciente COVID-19 en tratamiento con tocilizumab y corticoides ... Extract
GET 2020. IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome Extract
  • GET ä. Tocilizumab in COVID-19: Beware the risk of intestinal perforation Extract
  • GET 2020. Anti-IL6R role in treatment of COVID-19-related ARDS Extract
  • GET 2020. Hyper-inflammatory Syndrome in a Child With COVID-19 Treated Successfully With Intravenous Immunoglobulin and Tocilizumab. Extract
  • GET ä. Tocilizumab therapy reduced intensive care unit admissions and/or mortality in COVID-19 patients Extract
  • GET 2020. Tocilizumab for Treatment of Severe COVID-19 Patients: Preliminary Results from SMAtteo COvid19 REgistry (SMACORE). Extract
  • GET 2020. Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab. Extract
  • GET 2020. [Clinical observation of 6 severe COVID-19 patients treated with plasma exchange or tocilizumab]. Extract
  • GET 2020. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. Extract
  • GET 2020. Rapid resolution of cytokine release syndrome and favorable clinical course of severe COVID-19 in a kidney transplant recipient treated with tocilizumab. Extract
  • GET 2020. Tocilizumab Administration in Patients with SARS-CoV-2 Infection: Subcutaneous Injection versus Intravenous Infusion. Extract
  • GET 2020. Involvement of interleukin 6 in SARS-CoV-2 infection: siltuximab as a therapeutic option against COVID-19. Extract
  • GET 2020. Role of Interleukin-6 in Lung Complications in Patients With COVID-19: Therapeutic Implications. Extract
  • GET 2020. Javamide-II Inhibits IL-6 without Significant Impact on TNF-alpha and IL-1beta in Macrophage-Like Cells. Extract
  • GET 2020. Serum concentrations of interleukin-6 (IL-6) in the general adult population: possible implications for anti-IL-6 therapy in SARS-Cov-2 infection and IL-6-related diseases. Extract
  • GET 2020. Applied Clinical Pharmacology in a Crisis - Interleukin-6 Axis Blockade and COVID-19. Extract
  • GET 2020. Interleukin-6 Blockade Treatment for COVID-19 associated Cytokine Release Syndrome in a Patient with Poorly Controlled Chronic Myeloid Leukaemia. Extract
  • GET 2020. Tocilizumab not associated with increased infection risk after CAR T - Implications for COVID-19? Extract
  • GET 2020. Tocilizumab: from the rheumatology practice to the fight against COVID-19, a virus infection with multiple faces. Extract
  • GET 2020. The differential response to anti IL-6 treatment in COVID-19: the genetic counterpart. Extract
  • GET 2020. Tocilizumab in the treatment of a critical COVID-19 patient: a case report. Extract
  • GET 2020. Elevated interleukin-6 is associated with severity of COVID-19: a meta-analysis. Extract
  • GET 2020. COVID-19: Consider IL6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients. Extract
  • GET 2020. Early tocilizumab treatment could improve survival among COVID-19 patients. Extract
GET 2020. Practical aspects of targeting IL-6 in COVID-19 disease. Extract
  • GET 2020. Tociluzumab challenge: A series of cytokine storm therapy experience in hospitalized Covid-19 pneumonia patients. Extract
  • GET 2020. Feasibility of Tocilizumab in ICU patients with COVID-19. Extract
  • GET 2020. Tocilizumab administration in a refractory case of COVID-19. Extract
  • GET 2020. Utilizing tocilizumab for the treatment of cytokine release syndrome in COVID-19. Extract
  • GET 2020. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the 'culprit lesion' of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Extract
  • GET 2020. Tocilizumab therapy in five solid and composite tissue transplant recipients with early ARDS due to SARS-CoV-2. Extract
  • GET 2020. 'Toxic erythema' and eosinophilia associated with tocilizumab therapy in a COVID-19 patient. Extract
  • GET 2020. Tocilizumab: A Therapeutic Option for the Treatment of Cytokine Storm Syndrome in COVID-19. Extract
  • GET 2020. Tocilizumab for Hemophagocytic Syndrome in a Kidney Transplant Recipient With COVID-19. Extract
  • GET 2020. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Extract
  • GET 2020. Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. Extract
  • GET 2020. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy. Extract
  • GET 2020. Tocilizumab for severe COVID-19: A promising intervention affecting inflammation and coagulation. Extract
  • GET 2020. Impact of low dose tocilizumab on mortality rate in patients with COVID-19 related pneumonia. Extract
  • GET 2020. Re: Patiently waiting for the results of anti-IL 6 therapy in severe COVID-19 infection. Extract
  • GET 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. Extract
  • GET 2020. Effectiveness of Tocilizumab in a COVID-19 Patient with Cytokine Release Syndrome. Extract
  • GET 2020. Tocilizumab in Severe COVID-19 Pneumonia and Concomitant Cytokine Release Syndrome. Extract
GET 2020. Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. Extract
  • GET 2020. A... interleucina-6 en SARS-CoV-2/COVID-19. Extract
  • GET 2020. Use of subcutaneous tocilizumab in patients with COVID-19 pneumonia. Extract
  • GET 2020. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19. Extract
  • GET 2020. Interleukin-6 receptor antagonist therapy to treat SARS-CoV-2 driven inflammatory syndrome in a kidney transplant recipient. Extract
  • GET 2020. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. Extract
GET 2020. Case report: use of lenzilumab and tocilizumab for the treatment of coronavirus disease 2019. Extract
  • GET 2020. Rapid radiological improvement of COVID-19 pneumonia after treatment with tocilizumab. Extract
  • GET 2020. A Comprehensive Review on Tocilizumab in COVID-19 Acute Respiratory Distress Syndrome. Extract
  • GET 2020. Predictive factors of mortality in patients treated with tocilizumab for acute respiratory distress syndrome related to coronavirus disease 2019 (COVID-19). Extract
  • GET 2020. Outcomes in Patients with Severe COVID-19 Disease Treated with Tocilizumab - A Case- Controlled Study. Extract
  • GET 2020. Real-life experience of tocilizumab use in COVID-19 patients. Extract
  • GET 2020. Heart Transplant Recipient Patient with COVID-19 Treated with Tocilizumab. Extract
  • GET 2020. Tocilizumab en nino con leucemia linfoblastica aguda y sindrome de liberacion de citoquinas asociado a COVID-19. Extract
  • GET 2020. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized COVID-19 Patients: Survival and Clinical Outcomes. Extract
  • GET 2020. Biomarker variation in patients successfully treated with tocilizumab for severe coronavirus disease 2019 (COVID-19): results of a multidisciplinary collaboration. Extract
  • GET 2020. Compassionate Use of Tocilizumab for Treatment of SARS-CoV-2 Pneumonia. Extract
  • GET 2020. Profiling COVID-19 pneumonia progressing into the cytokine storm syndrome: Results from a single Italian Centre study on tocilizumab versus standard of care. Extract
  • GET 2020. Mit IL-6-Inhibitor gegen COVID-19 : Corona-Pandemie. Extract
  • GET 2020. Tocilizumab's efficacy in patients with Coronavirus Disease 2019 (COVID-19) is determined by the presence of cytokine storm. Extract
  • GET 2020. Citokinellenes terapia az uj tipusu koronavirus okozta megbetegedes (COVID-19) kezeleseben - tocilizumab elsokent valo alkalmazasa egy hazai infektologiai osztalyon. Extract
  • GET 2020. Higher levels of IL-6 early after tocilizumab distinguish survivors from non-survivors in COVID-19 pneumonia: a possible indication for deeper targeting IL-6. Extract
  • GET 2020. Successful Treatment of Severe COVID-19 Pneumonia With Clazakizumab in a Heart Transplant Recipient: A Case Report. Extract
Meine Werkzeuge
Namensräume
Varianten
Aktionen
Navigation
Werkzeuge